Detalhe da pesquisa
1.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
Antimicrob Agents Chemother
; 66(2): e0091621, 2022 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34871089
2.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23830355
3.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet
; 378(9787): 229-37, 2011 Jul 16.
Artigo
Inglês
| MEDLINE | ID: mdl-21763935
4.
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.
HIV Clin Trials
; 12(6): 313-22, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-22189150
5.
Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES).
HIV Clin Trials
; 11(4): 186-96, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20974574
6.
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Pediatr Infect Dis J
; 37(5): 459-465, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29023357
7.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lancet HIV
; 2(10): e427-37, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26423650
8.
Pharmacokinetics, safety and efficacy of maraviroc in treatment-experienced pediatric patients Infected with CCR5-tropic HIV-1
Pediatr. infect. dis. j
; 37(5): 459-465, May 2018. ilus, tab
Artigo
Inglês
| SES-SP, SES SP - Instituto de Infectologia Emílio Ribas, SES-SP | ID: biblio-1021502
9.
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
J Acquir Immune Defic Syndr
; 60(1): 33-42, 2012 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22343174
10.
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
AIDS
; 25(7): 929-39, 2011 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-21346512
11.
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
AIDS
; 22(12): 1389-97, 2008 Jul 31.
Artigo
Inglês
| MEDLINE | ID: mdl-18614861